Clare Kahn Ph.D. Joins Stoke Therapeutics Board of Directors on April 7, 2026

Stoke Therapeutics has announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. The company disclosed this development on Tuesday, April 7, 2026. Dr. Kahn brings extensive experience in the biotechnology and pharmaceutical industries to her new role with the organization.

The announcement highlights Dr. Kahn’s professional background, which includes significant contributions to scientific research and leadership within the life sciences sector. Stoke Therapeutics did not provide additional details about her specific responsibilities on the board or how her expertise will be utilized within the company’s strategic initiatives. Further information regarding this appointment can be found through official company channels or related announcements.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI